Table 2.

LV function as assessed by echocardiography

	Pre	Post
Heart rate, beats/min
Placebo	94.2 ± 5.1	86.9 ± 4.2
1 g/day	116.3 ± 11.8	74.1 ± 4.1*
2 g/day	109.8 ± 5.4	79.3 ± 5.3*
4 g/day	99.5 ± 7.4	70.8 ± 7.0*
Sham (4 g/day)	96.7 ± 6.3	64.1 ± 6.4*
Fractional shortening, %
Placebo	39.2 ± 1.3	38.4 ± 1.6
1 g/day	46.4 ± 2.8	44.5 ± 3.8
2 g/day	42.2 ± 1.2	45.4 ± 2.2
4 g/day	42.9 ± 1.6	40.1 ± 1.7
Sham (4 g/day)	39.1 ± 2.0	38.2 ± 2.7
LV internal diastolic diameter, cm
Placebo	4.15 ± 0.14	4.05 ± 0.14
1 g/day	4.08 ± 0.16	3.84 ± 0.17
2 g/day	4.11 ± 0.19	4.14 ± 0.17
4 g/day	3.92 ± 0.12	4.21 ± 0.17
Sham (4 g/day)	4.00 ± 0.02	3.90 ± 0.18
LV internal systolic diameter, cm
Placebo	2.49 ± 0.12	2.48 ± 0.14
1 g/day	2.20 ± 0.11	2.12 ± 0.16
2 g/day	2.44 ± 0.11	2.25 ± 0.08
4 g/day	2.30 ± 0.10	2.54 ± 0.13
Sham (4 g/day)	2.41 ± 0.09	2.40 ± 0.08

Values are means ± SE. LV, left ventricular; Pre, day before treatments began; Post, 3 mo after treatment began. Placebo, n = 13; 1 g/day, n = 5; 2 g/day, n = 8; 4 g/day, n = 10; and sham (4 g/day), n = 4.

^*P < 0.05, Pre vs. Post. Note that heart rate was not affected by the placebo treatment.